Pharmaceutical and Biotech plants for sale

14M Euro EBITDA growing Biotech CDMO in North Europe for sale

 

Fast growing Contract development and manufacturing organization (CDMO) in North Europe established EU – cGMP certified manufacturing facility (3.500 sq.m.), R&D area including QC labs of D, C and B grade. Fast growing (94%+ 5 years CAGR) revenue 75% in USA, 17% in Europe, 7% in ROW, providing services to big pharma, small-mid biotech companies.

Operates in biopharmaceutical CDMO market, offers fully integrated services, starting from cell line construction and process development up to cGMP production of biopharmaceutical products (DS & DP). Ex-Teva Biopharmaceuticals TOP management,

135 well trained employees. Financials: 2016 annual revenue – 28M Euro, EBITDA – 8M Euro, 2017E annual revenue – 38M Euro, EBITDA – 14M Euro, 2018B annual revenue – 50M Euro,

EBITDA – 21M Euro.

 

 

18+ M Euro revenue profitable, growing ANVISA distributor in São Paulo, Brazil for sale

 

Based in São Paulo, Specialised in the field of otorhinolaryngology and orthopaedic, represents two of the largest global suppliers with exclusivity in the Brazilian market. Clients of the company are mainly private (95%) with only 5% of government buyers. Its strategic position in the

 

Brazilian market is coupled by a solid image in the medical profession and clients with unblemished reputation and tradition for over 30 years. Growing annual revenue: 2016 – 14.7 M Euro, EBITDA (26%) 3.8 M Euro, 90 employees, no debts, net cash 1.5 M Euro. Motivation for sale: evaluating other business scenarios. Asking price 29 M Euro ( 95 M Brazilian Real ).

 

 

13M+ USD revenue growing profitable Pharmaceutical Company for sale in Brazil

 

Privately owned pharmaceutical company based in Brazil that produces and commercializes pharmaceutical products with its own brands. ANVISA approved plant, where it has registered 31 products. Sales: Liquids 62%, Solids 25%, Semisolids 13%; Distribution of Sales: OTC – 37%, Phytopharmaceuticals – 29%, Generic drugs – 17%, 42.500 m2 of industrial space recently acquired and approved by ANVISA for industrial use. Regional Tax Incentives: reduction of 75% of Income Tax

 

for 10 years, between other fiscal incentives for industrials. Revenues 2016: 43.5 M Reals (13M+ USD), EBITDA 2016: 4.7 M Reals (1.4 M USD), 330 Employees: Sales CAGR 2006-2016 12%

 

11M+ Euro annual revenue profitable and growing specialty pharmaceutical company in Poland

 

Company is looking for a JV / strategic partner / investor to successfully continue company growth. Company strong in Dermatology (70% of portfolio), CNS (15%), the rest 15% are OTC and generics. Own Marketing Authorizations and brands, majority of the products are in-licensed from well know dossier owners / manufacturers.

Company do not have own manufacturing plant. 25+ brands, 70 employees (55 reps) covering whole market. EBITDA 11%. Internal company valuation 28M Euro.

 

 

10M Euro revenue European fast growing company for sale

 

Fast growing pharmaceutical sales & marketing group with ca. 20 employees, product portfolio of 150 high quality Rx and OTC products (mostly EU CTD dossiers produced in EU GMP plants), therapeutic categories – central nervous system, cardiovascular, oncology, gastroenterology, respiratory, pain management, osteoporosis, allergology, infectology, around 600 MAs already granted globally, additional 50 MAs pending under ongoing regulatory procedures, main operations in

 

Germany, also in EU markets: UK, Denmark, Poland, Netherlands, Portugal, Italy, Spain, other and international sales in 33 countries. Cooperating with selected top-notch manufacturers in Europe and Asia. EU GMP and Wholesaler License, EU Import License, no real estate, no production plant, no bank loans, no pension liabilities. Carefully selected product portfolio potential to growth to 100+ M Euro in 2022. Financials: 10 M Euro revenue in 2017.

 

 

10M USD revenue, very profitable and growing Indian pharma company for sale ideal acquisition for companies willing to enter India market

 

Privately owned, HQ in Mumbai, fast growing pharmaceutical sales & marketing company in India with 350 field force and Top known brands over 20 years with great brand recall, 6 brands are #1 in the therapy areas. 350 field force covering

 

  • 000 GP’s, 7.500 Gynecologists, 6.200 Physicians, 4.000 Ortho, 3.800 General Surgeons, 2.100 ENT, 1.000 Dentists. Production in own 2 GMP plants (which are not for sale) and distribution to 1.000 Distributors covering whole India pharmacies (29 states).
  • Active in these therapy areas: Cephalosporin’s, Muscle Relaxant and Pain Management, Anti-ulcerants (PPI), Anti-diabetics, Anthelmintic, Spasm and Pain Management, Macrolides, Cough Syrup, Multivitamin Supplementation, Quinolone Combinations, Dermatological. Financials: 10 M USD Revenue, Gross Margin of 67%, 2.5M USD net profit, Asking price: ca. 30 M USD asking price (3x revenue, 12 profits)

 

8M Euro revenue pharmaceutical company for sale in North West Europe

 

The company manages the marketing, selling and distribution of pharmaceutical/medical supplies and devices in the several markets of North

 

Western Europe. The 8 million euro business growing and profitable business. Pharmaceuticals/devices currently represented include injectables, infusions, tablets and devices addressing the areas of pain management, women’s reproductive health, fungal infection and thyroid conditions.

 

Besides managing their own products, the company also represents international organisations that do have not have a local marketing, sales and distribution representative. Company do not have own production plant. Asking price 4M Euro

 

 

6M Euro pharmaceutical (dermatology) company in Italy for sale

 

Privately owned Italian pharmaceutical company founded in 2000, focused in dermatology field. Strong brands are amongst the most recommended by dermatologists in Italy. Product range of Cosmeceuticals, Medical Devices and Food Supplements for treatment of several dermatological pathologies. The Company has a team of 8 employees: a highly educated professional staff with substantial experience and are promoted by highly skilled 27 reps sales force (exclusive agents)

 

 

Financials: 2016 – 5.35M Euro revenue, 1.3M Euro EBITDA; 2017B – 6.0M Euro revenue, 1.4M Euro EBITDA; 24% EBITDA margin; 15% annual revenue growth No debts

 

Asking price 11M Euro

 

 

 

3.7+ USD profitable, growing PICS GMP running plant in Jakarta, Indonesia for sale

 

Established in 1984, PICS GMP running (last approval in 2016) manufacturing plant in Jakarta, Indonesia 5,167 sq.m. of land, 3,184 sq.m. of building and new machines installed in 2014 and 2015.

 

3 business divisions: Generics, Specialty and Herbal. Total of 164 SKU’s. Market leader for Anti-inflammatory product covers 60+% of anti inflammatory products in Indonesia.

Products are distributed to cities in 31 provinces in Indonesia through 23 distributors, such as Kimia Farma, Tempo, and Mensa Bina Sukses. Parcipating in government tenders. Production capacity 1 M tablets / day will be increased with the new machines. 50% is used capacity at the moment. 135 employees, Assets 11.4 M USD, Annual revenue 3.7 M USD,

 

EBITDA 22%, Asking price for 85% shares 11.5 M USD.

 

 

3,5 M€ revenue GMP plant and products for sale in Italy

 

Italian company with local and international operations, own products, 3,5 M€ turnover, oral solids and liquids, producing pharmaceuticals and Medical devices, 35 employees

 

Asset value: according to a recent evaluation the value of the building (manufacturing + warehouse + offices) is 7,3 M€ Debts total debts 3,4 M€

 

Running costs yearly in the range 4,2-4,5 M€ EBITDA 2016 < 0

 

Motivation for sale the owner is getting old and would like to retire. The sons are not interested in running the business being involved in other activities.

 

 

 

 

 

1.4M Euro revenue, profitable and modern Russian CMO with long term contracts for sale

 

Founded in 2011, State of the art, audited by TOP MNC pharma companies, CMO located in Moscow area with comfortable transport junction, Long-term contract manufacturing agreements (packaging) with 5+ TOP MNC pharmaceutical companies. Total area – 1.600 m2, including equipment stock, analytical laboratory and microbiological laboratory. CMO contracts includes primary and secondary packaging with the release control of the sterile solutions for injections in ampoules and syringes; Manufacturing capacities – 9 mln. pack. per year and used now 20%.

 

Possibility to expand production capacities to oral solid (tablets and capsules with the capacity of 2.5 bln. tab/caps. per year and/or non-sterile oral liquids.

The manufacturing site is approved by Russian GMP license and equipped with necessary communications and engineering equipment of the leading worldwide manufacturers including System for preparation, storage and distribution of purified water; Power supply system; Air preparation and conditioning system; Compressed air preparation and distribution system; Climatic parameter monitoring system; Security alarm and video monitoring system; Cooling-compressor equipment; Blister and cartooning machines. New equipment value app 1 M, land and building in on long term rent contract. 54 employees, annual revenue 1.4 M Euro, profitable, no loans from the banks.

 

 

1M+ Euro revenue Germany oncology company for sale

 

Privately owned pharmaceutical company, specialized in the field of oncology

 

(generics, parenteral), strong in the private sector market with clinical phase IV

studies. Five products actively marketed, four products to be launched.

 

Production is outsourced to well-known and reliable CMO’s. Supply chain is

secured. Licensor agreed to extend territory to pan EU, if requested. Sales >€1m

 

Euro, profitable, EBITDA 15%.

 

Asking price 4.5x revenues

 

 

 

 

1M Euro revenue Hospital businesses in Spain for sale

 

The company registers and distributes high quality pharmaceutical products (contrast agents for X-ray, CT and MRI) in an exclusive agreement; it holds own MAHs and Brands for the Spanish market and distributes these products to the hospitals. The company is about to launch a new generation of radiological products in the Spanish market, as well as registering and commercializing new oncology diagnostic products 10 people, 7 of which are sales force covering different regions. Annual revenue app. 1 M Euro, gross margin approximately 55%.

 

 

 

 

0.5M Euro revenue EU GMP running injectable manufacturing plant in Spain for sale

 

Profitable and growing CDMO (contract development & manufacturing organization) is available for sale. 15 employees, own land (5.000 sq.m), building (2.000 sq.m.), equipment, no debts. Manufacturing in glass container, PP container, PP bags, irrigation solutions. Provide services: i) Manufacturing of liquid parenteral solutions with terminal sterilization ii) Galenic development and analysis iii) Stability tests iv) Marketing, logistics and distribution. Competitive advantages: i) tax incentives, ii) no loans for asset iii) water from the ground, iv) European machineries v) lower labor costs due to region. Asking price 5 M Euro.

 

 

200 K Euro revenue HRT brand divestment in Germany

 

MA and brand in Germany in Hormone replacement therapy (HRT) for the relief of complaints during or after menopause as well as osteoporosis prevention. For sale is a longterm established and marketed product, German MA granted – no limits, no expiration + Trademark. Without promotion activities stable annual revenues of 200.000 Euro. Product is in the reimbursement list. Possibility to co-operate with existing CMO or own production to be discussed. Stock is available for a smooth business transaction.

 

 

 

US FDA approved operating plant for sale – Los Angeles

 

Located on East Cost, Manufacturing operation is approved by the US FDA. It has 43,800 square feet floor area consisting of Production, Production Services, Packaging, Warehouse & Dispensing, QC Labs, Maintenance& Utilities, Administration and office areas. Manufacturing Capacity: 1.5 Billion Tablets. The operating costs for the site (utilities, power and maintenance) are roughly $500K per year and expenses for 40

 

employees is 3 Million USD per year. A detailed break-up will be provided during the due diligence phase.

 

Object for sale is the land, building, equipment and other non-movable assets associated with the facility, running US FDA approved license. There will be no transfer of distribution licenses or any other licenses, no any products and no any services. This is a good as an entry for a company who can bring products/volumes himself. Asset value including land approx.. 10M USD. Asking price 15M USD

 

 

US FDA approved operating plant for sale – project Virginia

 

Place and factory: 53 acres located in Virginia; 424K sq. a. (under roof), production and packaging; 167K sq. a. Warehouse; 124K sq. a. Production, 31K sq. a. QA/QC lab, 53K sq. a. Office/Admin, 450 parking spaces, Residential: property includes additional 10 acres with 4 residential houses. A divestment from MNC Company having 10+ factories, an opportunity to provide CMO services for 2-3 years for existing 56+ ANDA’s while technology transfer will be transferred to seller another factories. No products included in the business for sale. Employees and Production expenses:

320 highly trained employees, site production expenses USD 56.5 million for 2017. Capacity: up to 3B oral solid dosages manufacturing and up to 3.5B doses packaging, Non-potent, Potent (OHC 4-5) and DEA (CII- CV) controlled OSD products, Focusing primarily on US/ Canada markets

 

 

450M+ USD revenue growing and profitable global pharmaceutical company for sale

 

450M+ USD revenue profitable global generic pharmaceutical company for sale with 100M+ EBITDA, own products 200+ EU CTD dossiers, global business in 100+ countries, 120 employees, own production plants, acting in cardiovascular, respiratory, CNS, gastroenterology, urology, other therapy areas.

 

160 M Euro revenue global cephalosporin products divestment

 

Products marketed in 100+ markets, 37% revenue in Europe, 30% APAC, 15% LATAM, 9% Middle East 9% Africa. Full range of dosage forms covering sterile injectibles, oral tablets, paediatric suspension, integrated oral and sterile 3 manufacturing plants based in Europe approved by EMEA and FDA, 870 – total number of employees in the factories, experienced management and

manufacturing expertise will be transferred as part of the business. Additional revenue stream from growing CMO business.


NBScience

contract research organization

stem cell therapy